Welcome to our dedicated page for Drugs Made In Amer Acqutn SEC filings (Ticker: DMAA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Drugs Made In America Acquisition Corp. (DMAA) provides direct access to the company’s regulatory reports as a Cayman Islands blank check issuer listed on The Nasdaq Stock Market LLC. These filings offer detailed insight into its corporate governance, officer appointments, consulting arrangements, and reporting status.
Key documents for Drugs Made In America Acquisition Corp. include current reports on Form 8-K, which disclose material events. One Form 8-K describes the resignation of the company’s Chief Financial Officer and principal financial and accounting officer and notes that the resignation was not due to any disagreement with the company. The same filing outlines the appointment of a new principal financial and accounting officer and a Master Services Agreement with Titan Advisory Services LLC, including compensation terms and share grants.
Another important filing type is the Form 12b-25 (NT 10-Q). DMAA’s NT 10-Q for the quarter ended September 30, 2025, explains why its Quarterly Report on Form 10-Q could not be filed by the deadline, citing the need for additional time to complete financial statements and obtain necessary review and signatures. The notification also confirms that all other required periodic reports had been filed and that no significant change in results of operations was anticipated for that quarter.
On this page, users can review Forms 10-K, 10-Q, 8-K, and NT 10-Q as they become available, along with any related exhibits. AI-powered summaries help explain the significance of these documents, highlight key terms such as officer changes, consulting agreements, and filing delays, and make it easier to interpret the technical language of SEC reports for Drugs Made In America Acquisition Corp.
Drugs Made In America Acquisition Corp. filed Amendment No. 1 to its definitive proxy statement to update voting thresholds and share counts tied to an Extraordinary General Meeting. The amendment states 33,517,143 Ordinary Shares outstanding as of the Record Date and elsewhere lists 33,717,143 Ordinary Shares as of the Record Date. It specifies that, assuming all Ordinary Shares are present, the Company will need 11,827,619 and alternatively 11,760,953 Public Shares to approve the Extension Proposal, and 6,241,429 and alternatively 6,141,429 Public Shares to approve the Adjournment Proposal. The Amendment replaces Article 48.7 and is dated April 16, 2026.
Drugs Made In America Acquisition Corp., a Cayman Islands-based blank check company, filed its annual report detailing progress and risks as it searches for a merger target. The SPAC raised $231.15 million in trust from its IPO and private placements and reported 2025 net income of $5.94 million, driven by $8.76 million of interest on trust investments.
The company remains a shell with no operations and faces a going concern uncertainty due to limited cash outside the trust and a deadline to complete a business combination. It is seeking to extend its combination period up to April 29, 2027 through shareholder approval and sponsor-funded monthly trust contributions.
Governance shifted significantly after the prior CEO resigned in early 2026 following issues at an affiliated SPAC sponsor, and a new CEO and CFO were appointed. DMAA secured a $500,000 convertible note commitment, including a $100,000 interim loan, and signed a non-binding LOI with Power Analytics Global Corp. for a potential $1.0 billion de‑SPAC transaction, which remains subject to negotiation and diligence. Management also disclosed material weaknesses in internal controls and plans remediation.
Drugs Made in America Acquisition Corp. is asking shareholders to approve changes that would give it up to 12 extra months, from April 29, 2026 to April 29, 2027, to complete a business combination.
Each one-month extension would require the sponsor to loan the lesser of $300,000 or $0.04 per non‑redeemed public share into the trust account. Public shareholders can redeem shares for about $10.52 per share, based on roughly $242 million held in the trust as of the record date, regardless of how they vote. If the extension is not approved and no deal closes by the current deadline, the SPAC will redeem all public shares and wind up.
Drugs Made in America Acquisition Corp. entered into a non-binding letter of intent with Power Analytics Global Corp. on April 7, 2026 for a potential de-SPAC transaction that would take Power Analytics public. The LOI anticipates a Target valuation of approximately $1.0 billion, subject to adjustment based on due diligence, capital structure, net debt, working capital and market conditions, and will require negotiation and execution of a definitive business combination agreement.
Drugs Made in America Acquisition Corp. submitted a Form 12b-25 notifying the SEC it could not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company states it could not, without unreasonable effort or expense, compile required financial statements and expects to file on or before April 15, 2026.
The board of Drugs Made in America Acquisition Corp. is soliciting shareholder approval to amend its charter to extend the deadline to complete an initial business combination beyond the current April 29, 2026. The proxy describes monthly one‑month extension periods funded by sponsor contributions or loans, redemption rights for Public Shareholders and the quorum and vote thresholds required under Cayman Islands law.
The company completed its IPO of 20,000,000 Units at $10.00 each (gross proceeds $200,000,000) and, as disclosed, had 33,517,143 Ordinary Shares outstanding on the date of the proxy, including 23,000,000 Public Shares and 10,517,143 Founder Shares. If the Extension Proposal is approved, holders may redeem Public Shares for a pro rata portion of funds in the Trust Account by following the stated tender procedures.
Drugs Made In America Acquisition Corp. entered into a financing arrangement with BV Advisory Partners, LLC, starting with a $100,000 interim convertible note as the first tranche of a contemplated $500,000 funding commitment. The note matures in six months, bears no interest, and can convert, at the investor’s option after a business combination, into shares of the combined entity at a 35% discount to the market price at conversion.
The company plans to use the proceeds for accounting, audit, and other business combination-related expenses and has not yet agreed to a merger. Under the related investment agreement, a second tranche of $200,000 is expected within 21 days, with remaining amounts available on an as-needed basis. The investor is also being offered at least 40% of the economic benefit equivalent to sponsor-level economics and has introduced a potential business combination target focused on artificial intelligence, machine learning, quantum analytics, and cybersecurity solutions, though no letter of intent or definitive agreement has been signed.
Drugs Made In America Acquisition Corp. reported leadership changes following issues at an affiliated SPAC’s working capital account. The sponsor of Drugs Made In America Acquisition II Corp. withdrew an aggregate $1,100,000 from the affiliate’s working capital account, including $325,000 to repay a working capital note and $208,000 for other offering costs and expenses. The affiliate’s financial statements also showed a $566,269 overpayment to the sponsor, and the sponsor later withdrew no less than $200,000 more to pay expenses unrelated to the affiliate. After the affiliate’s board directed the sponsor to return the full overpayment amount and learned on February 12, 2026 that it could not be repaid, the boards of the affiliate and the company requested the resignation of Lynn Stockwell as Chief Executive Officer, Executive Chair, and director. The board received her resignation effective February 28, 2026 and removed her from all roles. On the same date, Roger Bendelac was appointed Chief Executive Officer of the company; his compensation will be determined later.
Drugs Made In America Acquisition Corp. (DMAA) reported net income of $2.18 million for the quarter and $5.73 million for the nine months ended September 30, 2025, driven almost entirely by $6.45 million of interest earned on the cash and investments held in its trust account. Operating expenses remain modest, with general and administrative costs of $263,703 for the quarter and $726,547 year-to-date as the SPAC continues to search for a pharmaceutical-sector business combination.
The company’s balance sheet shows $237.6 million of cash and investments in the trust account, backing 23,000,000 ordinary shares subject to redemption at $10.33 per share, while cash outside the trust is only $717 and working capital shows a deficit of $428,415. Management discloses that the mandatory liquidation deadline—15 months after the IPO closing, or up to 21 months if extensions are funded—raises substantial doubt about the company’s ability to continue as a going concern if no business combination is completed within this “Combination Period.”